Tag: NEU

Neuren Pharmaceuticals ASX NEU FDA grants orphan drug designation Phelan-McDermid Pitt Hopkins syndrome

Neuren Pharma granted orphan drug status for treatment of Phelan-McDermid, Pitt Hopkins and Angelman syndromes

A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted orphan drug designation by the US Food and Drug Administration. D...
Neuren Pharmaceuticals ASX NEU NNZ-2591 Pitt Hopkins Angelman syndrome model

Neuren’s NNZ-2591 drug candidate alleviates Pitt Hopkins and Angelman syndrome symptoms

Neuren Pharmaceuticals (ASX: NEU) has revealed positive pre-clinical results for its NNZ-2591 drug candidate in treating Pitt Hopkins and Angelman syndromes. According to Neuren, its NNZ-2591 drug ...
Neuren Pharmaceuticals ASX NEU ACADIA Pharma trofinetide Rett Syndrom licence US

Neuren Pharmaceuticals receives first payment in Rett drug licence deal

Neuren Pharmaceuticals (ASX: NEU) has received the first US$10 million payment under a recently announced licence deal with US-based ACADIA Pharmaceuticals to develop its drug trofinetide to treat pat...
Neuren Pharmaceuticals NEU Phase 3 FDA approval Rett syndrome

FDA greenlights Neuren Pharmaceuticals to kick-off next trial for Rett drug

Melbourne-based Neuren Pharmaceuticals (ASX: NEU) reported the US Food and Drug Administration has given the greenlight for the company to start phase three trials for its drug trofinetide, which is u...